Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Frailty × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Glioblastoma 40 Glioma 14 Neuroblastoma 13 Brain Neoplasms 12 Astrocytoma 9 Rhabdomyosarcoma 8 Sarcoma, Ewing 7 Neoplasms 7 Recurrence 6 Oligodendroglioma 5 Medulloblastoma 5 Sarcoma 4 Osteosarcoma 4 Melanoma 4 Small Cell Lung Carcinoma 3 Lymphoma 3 Gliosarcoma 3 Diffuse Intrinsic Pontine Glioma 3 Wilms Tumor 2 Ovarian Neoplasms 2 Neuroendocrine Tumors 2 Neuroectodermal Tumors, Primitive 2 Neoplasm Metastasis 2 Hepatoblastoma 2 Fallopian Tube Neoplasms 2 Ependymoma 2 Colorectal Neoplasms 2 Spinal Cord Neoplasms 1 Solid Tumor 1 Rhabdoid Tumor 1

Interventions

Geriatric Assessment 3 microcrystalline cellulose 1 epigallocatechin gallate 1 diacetamate 1 Therapeutics 1 Temozolomide 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Standard of Care 1 Psychosocial Intervention 1 Observation 1 Methods 1 Enhanced Recovery After Surgery 1 Data Collection 1 Ascorbic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05554003 2024-11-18

MeTe

European Institute of Oncology

Phase 2 Recruiting

Frailty, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡